What caused BANB.SW stock to spike intraday today?

BANB.SW stock rose after Bachem’s 12 March earnings update and commentary on peptide demand, pushing price to CHF60.25. Volume spiked to 56,926 shares, nearly three times average, as traders priced renewed commercial activity into the stock.

What is Meyka AI’s short-term BANB.SW stock forecast?

Meyka AI's forecast model projects a near-term target of CHF64.13 for BANB.SW stock, implying about 6.44% upside from the current CHF60.25. Forecasts are model-based projections and not guarantees.

How is BANB.SW stock valued relative to peers?

BANB.SW shows a trailing PE of 33.07 and PB of about 3.26, which is richer than Basic Materials peers (avg PE ~22.51). Strong margins and low leverage support valuation but increase execution risk if growth slows.

What key risks should investors monitor for BANB.SW stock?

Monitor long inventory days (378.02), negative free cash flow per share (CHF-1.59), and contract timing with pharma clients. These operational factors can pressure the stock if demand or execution weakens.

CH Stocks

BANB.SW jumps 9.65% to CHF60.25 on SIX: intraday gain signals renewed peptide demand

ByDanny Kontos March 13, 2026March 13, 2026

BANB.SW stock led Swiss gainers intraday on 13 Mar 2026, rising 9.65% to CHF60.25 on the SIX exchange after a fresh earnings-related update and stronger intraday buying. Bachem Holding AG (BANB.SW) outperformed peers in the Basic Materials sector as volume reached 56,926 shares, nearly three times average. Investors reacted to the company’s March announcement and higher demand signals for peptide active ingredients. We break down the drivers, valuation, technicals, and Meyka AI’s short-term forecast for BANB.SW stock.